Compare BOOT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOT | IOVA |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | BOOT | IOVA |
|---|---|---|
| Price | $170.23 | $6.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $223.09 | $9.00 |
| AVG Volume (30 Days) | 738.6K | ★ 19.8M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | 14.84 |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.98 | $47.74 |
| Revenue Next Year | $13.91 | $40.31 |
| P/E Ratio | $71.44 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $133.18 | $1.76 |
| 52 Week High | $210.25 | $6.92 |
| Indicator | BOOT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 70.39 |
| Support Level | $171.68 | $3.57 |
| Resistance Level | $205.38 | N/A |
| Average True Range (ATR) | 6.31 | 0.41 |
| MACD | 2.28 | 0.15 |
| Stochastic Oscillator | 100.00 | 79.39 |
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.